23 Feb Cabaletta Bio
Steven Nichtberger, M.D., President, CEO, and Co-Founder
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™), in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor T cells that are designed to selectively bind and eliminate specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase I clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in 2020. The company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and designed as a potential treatment for patients with MuSK-associated myasthenia gravis.